L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells

Carcinogenesis

Volumn 32, Issue 3, 2011, Pages 262-270

  Doberstein, Kai ^a   Wieland, Anja ^b   Lee, Sophia B Boyoung ^a   Blaheta, Roman A Alexander ^c   Wedel, Steffen ^c   Moch, Holger ^d   Schraml, Peter ^d   Pfeilschifter, Josef ^a   Kristiansen, Glen ^d   Gutwein, Paul ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; CYCLIN D1; NERVE CELL ADHESION MOLECULE L1; RAPAMYCIN; SMALL INTERFERING RNA; SUNITINIB; TRANSCRIPTION FACTOR PAX8; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLEAR CELL RENAL CELL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG CYTOTOXICITY; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY COLLECTING TUBULE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; TISSUE MICROARRAY; WESTERN BLOTTING;

EID: 79952293565     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq249     Document Type: Article

References (43)

1. Rini, B.I. et al. (2008) Renal cell carcinoma. Curr. Opin. Oncol., 20, 300-306.
2. Gupta, K. et al. (2008) Epidemiologic and socioeconomic burden of meta-static renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev., 34, 193-205.
3. Schrader, A.J. et al. (2006) Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J. Cancer Res. Clin. Oncol., 132, 137-149.
4. Novak-Hofer, I. (2007) The L1 cell adhesion molecule as a target for radio-immunotherapy. Cancer Biother. Radiopharm., 22, 175-184.
5. Moos, M. et al. (1988) Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature, 334, 701-703.
6. Gutwein, P. et al. (2003) ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J., 17, 292-294.
7. Allory, Y. et al. (2005) The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin. Cancer Res., 11, 1190-1197.
8. Huszar, M. et al. (2006) Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum. Pathol., 37, 1000-1008.
9. Raveh, S. et al. (2009) L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett., 2, 137-145.
10. Chalepakis, G. et al. (1994) Characterization of Pax-6 and Hoxa-1 binding to the promoter region of the neural cell adhesion molecule L1. DNA Cell Biol., 13, 891-900.
11. Bouchard, M. et al. (2002) Nephric lineage specification by Pax2 and Pax8. Genes Dev., 16, 2958-2970.
12. Robson, E.J. et al. (2006) A PANorama of PAX genes in cancer and development. Nat. Rev. Cancer, 6, 52-62.
13. Luu, V.D. et al. (2009) Loss of VHL and hypoxia provokes PAX2 upregulation in clear cell renal cell carcinoma. Clin. Cancer Res., 15, 3297-3304.
14. Nyhan, M.J. et al. (2008) Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem. Soc. Trans., 36, 472-478.
15. Hergovich, A. et al. (2003) Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat. Cell Biol., 5, 64-70.
16. Lee,S.B. et al. (2009) ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J. Invest. Dermatol., 3, 763-773.
17. Schramme, A. et al. (2008) Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int., 74, 328-338.
18. Elbashir, S.M. et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
19. Fritzsche, F.R. et al. (2008) Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clin. Cancer Res., 14, 7035-7042.
20. Gutwein, P. et al. (2009) Downregulation of junctional adhesion molecule-A is involved in the progression of clear cell renal cell carcinoma. Biochem. Biophys. Res. Commun., 380, 387-391.
21. Mechtersheimer, S. et al. (2001) Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J. Cell Biol., 155, 661-673.
22. Banks, R.E. et al. (2006) Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res., 66, 2000-2011.
23. Meech, R. et al. (1999) A binding site for homeodomain and Pax proteins is necessary for L1 cell adhesion molecule gene expression by Pax-6 and bone morphogenetic proteins. Proc. Natl Acad. Sci. USA, 96, 2420-2425.
24. Narlis, M. et al. (2007) Pax2 and pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney. J. Am. Soc. Nephrol., 18, 1121-1129.
25. Gavert, N. et al. (2008) L1-CAM in cancerous tissues. Expert Opin. Biol. Ther., 8, 1749-1757.
26. Meli, M.L. et al. (1999) Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells. Int. J. Cancer, 83, 401-408.
27. Zecchini, S. et al. (2008) The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res., 68, 1110-1118.
28. Li, S. et al. (2009) L1 cell adhesion molecule is a novel independent poor prognostic factor of extrahepatic cholangiocarcinoma. Clin. Cancer Res., 15, 7345-7351.
29. Sebens, M.S. et al. (2007) Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene, 26, 2759-2768.
30. Stoeck, A. et al. (2007) L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol. Oncol., 104, 461-469.
31. Daponte, A. et al. (2008) L1 (CAM) (CD171) in ovarian serous neoplasms. Eur. J. Gynaecol. Oncol., 29, 26-30.
32. Kaelin, W.G. Jr. (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer, 8, 865-873.
33. Gnarra, J.R. et al. (1996) Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim. Biophys. Acta, 1242, 201-210.
34. Iliopoulos, O. et al. (1995) Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med., 1, 822-826.
35. Schoenfeld, A. et al. (1998) A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl Acad. Sci. USA, 95, 8817-8822.
36. Patard, J.J. et al. (2008) Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int. J. Cancer, 123, 395-400.
37. Patard, J.J. et al. (2009) Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br. J. Cancer, 101, 1417-1424.
38. Gavert, N. et al. (2005) L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J. Cell Biol., 168, 633-642.
39. Tong, G.X. et al. (2009) Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod. Pathol., 22, 1218-1227.
40. Kozmik, Z. et al. (1993) Alternative splicing of Pax-8 gene transcripts is developmentally regulated and generates isoforms with different transactivation properties. Mol. Cell. Biol., 13, 6024-6035.
41. Dressler, G.R. (2006) The cellular basis of kidney development. Annu. Rev. Cell Dev. Biol., 22, 509-529.
42. Eccles, M.R. et al. (2002) PAX genes in development and disease: the role of PAX2 in urogenital tract development. Int. J. Dev. Biol., 46, 535-544.
43. Muratovska, A. et al.;1; (2003) Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene, 22, 7989-7997.